STEEL
OtherRelatively heavy strength training
NCT Number: NCT06299722
We aim to include 60 children and adolescents aged 10 to 19 years who have undergone successful treatment for leukemia or lymphoma. Based on randomization, they will either 1) commence 16 weeks of training with STEEL or 2) commence 16 weeks of circuit training. STEEL training involves exercises for major muscle groups using free weights, body weight, or tailored machines. Circuit training is structured similarly to previous training for the target group and includes exercises using body weight, exercise balls, and rings. The training takes place in local centers either with friends or with other participants in the project. Before starting participation in the project, the child/adolescent and their parents or guardians will receive information about late effects, diet, sleep, and exercise, providing guidance and support regarding the project elements. The effects of the two training modalities will be evaluated based on self-reported quality of life, muscle strength, muscle mass, bone mineral content, fitness, and markers of metabolic syndrome (BMI, waist circumference, blood pressure, and blood analysis).
Looking for future studies?
Notify MeThe trial is designed as a national randomised clinical trial. Participants will be stratified by sex and block randomised (block sizes of 2 to 6) at 1:1 to either STEEL or the circuit training programme. A researcher not involved in the trial will generate the allocation sequence using a random number generator and is the only person who will know the block sizes. The study will be conducted at Aalborg University Hospital, Rigshospitalet, Odense University Hospital, and Aarhus University Hospital and was designed in collaboration with parents of childhood cancer survivors and an adult childhood cancer survivor suffering from late effects. Participants must attend three examinations at their respective hospitals: baseline and after 8 and 16 weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Relatively heavy strength training
Circuit training
Time frame: Baseline and at the 8-week and 16-week follow-ups
Measured in Nm based on tests of knee extension and flexion and elbow extension and flexion using handheld dynamometry
Time frame: During baseline and at the 16-week follow-up
We will use the Danish version of the Pediatric Quality of Life Inventory (PedsQL™) 4.0 Generic Core scales and the PedsQL™ Multidimensional Fatigue scales (5,9) to assess health-related quality of life. The PedsQL is a brief 23-item measurement model that evaluates quality of life in four areas: physical, emotional, social and school functioning. The questionnaire scores range from 0 to 100, and higher scores indicate better quality of life. The PedsQL™ Multidimensional Fatigue includes 18 questions related to fatigue and uses the same scoring as the PedsQL
Time frame: Weekly throughout the 16-week intervention
We will assess participants' step counts throughout the intervention using a Garmin vívosmart® 5 watch (Garmin Ltd., Kansas, USA).
Time frame: Weekly throughout the 16-week intervention
We will assess participants' caloric expenditure (KCAL) throughout the intervention using a Garmin vívosmart® 5 watch (Garmin Ltd., Kansas, USA).
Time frame: During the first and last training sessions of the 16-week intervention
we will test the 1 repetition maximum (RM) in the leg press and chest press machines
Time frame: During baseline and at the 16-week follow-up
We will measure the bone mineral density of the lumbar spine (L1-L4) calculated as the Z-score and body composition (%body fat, lean body mass, and skeletal muscle mass) by a dual-energy-X-ray absorptiometry scanner located at each hospital.
Time frame: Baseline and at the 8-week and 16-week follow-ups
Using a digital hand dynamometer, we will measure continuous isometric handgrip force and rate of force development.
Time frame: Baseline and at the 8-week and 16-week follow-ups
We will use a 30-second sit-to-stand test to evaluate strength, endurance, and rate of force development of the lower extremities.
Time frame: Baseline and at the 8-week and 16-week follow-ups
We will perform a 6-minute walk test to evaluate cardiorespiratory fitness and walking endurance
Time frame: Throughout the 16-week intervention
Exercise compliance and fidelity will be measured using training diaries, which the participants fill out themselves after the unsupervised training sessions and by the physiotherapist during the supervised training sessions. Exercise compliance relates to whether the training sessions have been performed, and fidelity relates to whether the exercises have been performed as prescribed regarding the number of repetitions, sets, and intensity.
Time frame: Throughout the 16-week intervention
Adverse events will be collected throughout the trial and graded 1 to 5 according to the Common Terminology Criteria for Adverse Events v4.03. Participants are asked to contact the responsible clinician at the hospital where they were enrolled as soon as they experience any adverse event.
Time frame: During baseline and at the 16-week follow-up
We will use a 0 (no pain) to 10 (worst pain imaginable) Numerical Rating Scale to assess movement-evoked pain during the past week
Time frame: During the 16-week follow-up
We will assess participant satisfaction with their respective intervention using a 5-point rank scale ranging from 'very dissatisfied' to 'very satisfied'.
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in mmol/L
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in mmol/mol
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in mU/L
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in ng/mL
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in mmol/L
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in mmol/L
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in mmol/L
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in mmol/L
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in mmol/L
Time frame: During baseline and at the 16-week follow-up
Analysed from a blood sample and measured in pg/mL
Time frame: During baseline and at the 16-week follow-up
Calculated as fasting plasma glucose (mmol/L x fasting plasma glucose ((μU/L)/22.5) to estimate β-cell function (HOMA-B) and insulin-resistance (HOMA-IR2)
Time frame: During baseline and at the 16-week follow-up
Measured as kg/m² for adolescents aged 18 or 19 years and BMI standard deviation (SD) scores for children aged 10-17 years based on national reference material.
Time frame: During baseline and at the 16-week follow-up
Measured in kilograms based on dual-energy X-ray absorptiometry (DXA)
Time frame: During baseline and at the 16-week follow-up
Measured in kilograms based on dual-energy X-ray absorptiometry (DXA)
Time frame: During baseline and at the 16-week follow-up
Measured in kilograms based on dual-energy X-ray absorptiometry (DXA) adjusted for sex and pubertal stage
Time frame: During baseline and at the 16-week follow-up
Measured in centimetres
Time frame: During baseline and at the 16-week follow-up
Visual illustration of Tanner staging (I-V) regarding both genders
Time frame: During baseline and at the 16-week follow-up
Measured in mmHg
Aalborg University
Other
Strength Training Exercises to Minimise Late Effects of Childhood Leukaemia or Lymphoma Among Adolescents - The STEEL Study - a National Multicenter Randomised Controlled Study
Acronym: STEEL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05364372
Behavior, Cancer
Tucson, Arizona, United States
View Trial DetailsNCT01445483
Brain Diseases, Brain Metastasis
Bethesda, Maryland, United States
View Trial DetailsNCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial DetailsNCT03556384
Brain Diseases, Cancer
La Jolla, California, United States
View Trial Details